

Jaime Feliu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9511293/publications.pdf>

Version: 2024-02-01

104
papers

2,282
citations

249298

26
h-index

299063

42
g-index

109
all docs

109
docs citations

109
times ranked

3185
citing authors

#	ARTICLE	IF	CITATIONS
1	Yttrium-90 transarterial radioembolization in patients with gastrointestinal malignancies. <i>Clinical and Translational Oncology</i> , 2022, 24, 796-808.	1.2	4
2	Clinicopathological characteristics and outcomes of patients with deficient mismatch repair colorectal cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 181-181.	0.8	1
3	Prognosis Stratification Tools in Early-Stage Endometrial Cancer: Could We Improve Their Accuracy?. <i>Cancers</i> , 2022, 14, 912.	1.7	4
4	Prediction of Chemotoxicity, Unplanned Hospitalizations and Early Death in Older Patients with Colorectal Cancer Treated with Chemotherapy. <i>Cancers</i> , 2022, 14, 127.	1.7	9
5	Identification of Carcinogenesis and Tumor Progression Processes in Pancreatic Ductal Adenocarcinoma Using High-Throughput Proteomics. <i>Cancers</i> , 2022, 14, 2414.	1.7	2
6	Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials. <i>ESMO Open</i> , 2022, 7, 100485.	2.0	17
7	Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?. <i>Clinical and Translational Oncology</i> , 2021, 23, 536-542.	1.2	5
8	Undertreatment and overtreatment in older patients treated with chemotherapy. <i>Journal of Geriatric Oncology</i> , 2021, 12, 381-387.	0.5	14
9	Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy. <i>Clinical and Translational Oncology</i> , 2021, 23, 1185-1192.	1.2	12
10	Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. <i>Clinical and Translational Oncology</i> , 2021, 23, 1245-1252.	1.2	21
11	Prediction of Unplanned Hospitalizations in Older Patients Treated with Chemotherapy. <i>Cancers</i> , 2021, 13, 1437.	1.7	10
12	SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 988-1000.	1.2	23
13	Rondas multidisciplinares en oncologÃa y hematologÃa: Â¿son superiores a los equipos de respuesta rÃápida?. <i>Medicina Intensiva</i> , 2021, 45, 127-128.	0.4	0
14	Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice?. <i>Cancers</i> , 2021, 13, 1986.	1.7	43
15	Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab. <i>Scientific Reports</i> , 2021, 11, 7402.	1.6	1
16	Development and Validation of an Early Mortality Risk Score for Older Patients Treated with Chemotherapy for Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 1615.	1.0	8
17	Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience. <i>Clinical and Translational Oncology</i> , 2021, 23, 1838-1846.	1.2	1
18	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5020-5027.	3.2	37

#	ARTICLE	IF	CITATIONS
19	Abstract CT177: A multi-center phase 2a trial of the CXCR4 inhibitor motixafortide (BL-8040) (M) in combination with pembrolizumab (P) and chemotherapy (C), in patients with metastatic pancreatic adenocarcinoma (mPDAC). <i>Cancer Research</i> , 2021, 81, CT177-CT177.	0.4	2
20	Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. <i>ESMO Open</i> , 2021, 6, 100223.	2.0	18
21	Multiplexed magnetic beads-assisted amperometric bioplatfoms for global detection of methylations in nucleic acids. <i>Analytica Chimica Acta</i> , 2021, 1182, 338946.	2.6	10
22	Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 543-553.	1.1	14
23	Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2021, 27, 6775-6793.	1.4	12
24	Gp-100 as a Novel Therapeutic Target in Uveal Melanoma. <i>Cancers</i> , 2021, 13, 5968.	1.7	16
25	Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?. <i>Cancer Cell International</i> , 2021, 21, 646.	1.8	6
26	Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 457-467.	1.2	29
27	Situation, challenges, and SEOM recommendations for the future of undergraduate education in Oncology in Spain. <i>Clinical and Translational Oncology</i> , 2020, 22, 1049-1058.	1.2	0
28	VITAL phase 2 study: Upfront 5-Fluorouracil, mitomycin, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09). <i>Cancer Medicine</i> , 2020, 9, 1008-1016.	1.3	12
29	Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review. <i>Clinical and Translational Oncology</i> , 2020, 22, 1288-1294.	1.2	5
30	Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 4015.	1.0	7
31	Comprehensive Characterization of the Mutational Landscape in Localized Anal Squamous Cell Carcinoma. <i>Translational Oncology</i> , 2020, 13, 100778.	1.7	8
32	Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study. <i>Oncologist</i> , 2020, 25, e1516-e1524.	1.9	20
33	Prognostic value of neutrophil-to-lymphocyte ratio and other inflammatory markers in patients with high-risk soft tissue sarcomas. <i>Clinical and Translational Oncology</i> , 2020, 22, 1849-1856.	1.2	12
34	Genetic Profile and Functional Proteomics of Anal Squamous Cell Carcinoma: Proposal for a Molecular Classification. <i>Molecular and Cellular Proteomics</i> , 2020, 19, 690-700.	2.5	4
35	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , 2020, 26, 878-885.	15.2	297
36	Efficacy and safety of the combination of aflibercept with fluorouracil, leucovorin, and irinotecan in patients aged 70 years and older with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen in Spain: A retrospective multicenter cohort study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 124-124.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	1.9	12
38	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. ESMO Open, 2019, 4, e000519.	2.0	5
39	Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-“Epidermal Growth Factor Receptor Therapy. JCO Precision Oncology, 2019, 3, 1-16.	1.5	12
40	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). Clinical and Translational Oncology, 2019, 21, 46-54.	1.2	40
41	Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).. Journal of Clinical Oncology, 2019, 37, TPS471-TPS471.	0.8	5
42	Delphi consensus of an expert committee in oncogeriatrics regarding comprehensive geriatric assessment in seniors with cancer in Spain. Journal of Geriatric Oncology, 2018, 9, 337-345.	0.5	16
43	Can we avoid the toxicity of chemotherapy in elderly cancer patients?. Critical Reviews in Oncology/Hematology, 2018, 131, 16-23.	2.0	25
44	ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolinâ€dependent invasiveness, and these effects can be ameliorated using the <scp>BET</scp> inhibitor apabetalone. Molecular Oncology, 2018, 12, 1735-1752.	2.1	79
45	Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients. Neoplasia, 2018, 20, 678-686.	2.3	7
46	First-line treatment with panitumumab plus FOLFIRI in elderly patients with <i>RAS/BRAF</i> wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial.. Journal of Clinical Oncology, 2018, 36, TPS3618-TPS3618.	0.8	2
47	Molecular characterization of breast cancer cell response to metabolic drugs. Oncotarget, 2018, 9, 9645-9660.	0.8	22
48	Phase II study of panitumumab, 5-fluorouracil, mitomycin-c and radiotherapy treatment in patients with non-metastatic squamous cell carcinoma of the anal canal: safety and efficacy results (VITAL) Tj ETQq0 0 0 rgBT. #Overlock 10 Tf 50	0.8	0
49	Functional proteomics outlines the complexity of breast cancer molecular subtypes. Scientific Reports, 2017, 7, 10100.	1.6	50
50	Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases. Future Oncology, 2017, 13, 2065-2082.	1.1	10
51	Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain. Clinical and Translational Oncology, 2017, 19, 498-507.	1.2	15
52	A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Annals of Oncology, 2017, 28, 2142-2148.	0.6	30
53	Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer. PLoS ONE, 2017, 12, e0183452.	1.1	11
54	Long-term cancer survivors: Satisfaction with medical care and information received during the diagnosis and treatment of cancer.. Journal of Clinical Oncology, 2017, 35, e21573-e21573.	0.8	0

#	ARTICLE	IF	CITATIONS
55	SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1172-1178.	1.2	27
56	Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)]. <i>Journal of Clinical Oncology</i> , 2016, 34, 583-583.	0.8	0
57	Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0116527.	1.1	34
58	Clinical guideline SEOM: hepatocellular carcinoma. <i>Clinical and Translational Oncology</i> , 2015, 17, 988-995.	1.2	29
59	Gene expression differences in primary colorectal tumors and matched liver metastases: chemotherapy related or tumoral heterogeneity?. <i>Clinical and Translational Oncology</i> , 2015, 17, 322-329.	1.2	5
60	Untreated metastatic diffuse gastric adenocarcinoma (DGAC): Randomized phase III study of S-1 and cisplatin vs. 5-FU and cisplatin (the DIGEST trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4015-4015.	0.8	56
61	Radiologic and pathologic prognostic factors after neoadjuvant chemotherapy for T3 rectal cancer (RC): 3-year update GEMCAD 0801-trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 643-643.	0.8	3
62	“First chemotherapy” or “first local” approach for liver-only synchronic metastasis rectal cancer? A single institution experience.. <i>Journal of Clinical Oncology</i> , 2015, 33, 780-780.	0.8	0
63	Predictive serum biomarkers in metastatic colorectal cancer (mCRC) patients treated in the BECOX trial with oxaliplatin-capecitabine (CAPOX) plus bevacizumab (BVZ) (GEMCAD 09-01).. <i>Journal of Clinical Oncology</i> , 2015, 33, e14647-e14647.	0.8	0
64	Predictive factors of early death after a comprehensive geriatric assessment in elderly cancer patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20530-e20530.	0.8	0
65	Predictive factors of grade 3-5 toxicity in elderly cancer patients treated with chemotherapy: A prospective multicenter study (TEP study: Toxicity in Elderly Patient).. <i>Journal of Clinical Oncology</i> , 2015, 33, e20535-e20535.	0.8	0
66	Gene expression markers of resistance to capecitabine-oxaliplatin-bevacizumab treatment in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e14555-e14555.	0.8	0
67	A Phase I, Dose-Finding Study of Sorafenib in Combination with Gemcitabine and Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Grupo Espa�ol Multidisciplinario en C�ncer Digestivo (GEMCAD) Study. <i>PLoS ONE</i> , 2014, 9, e82209.	1.1	11
68	Preoperative Chemotherapy in Patients With Intermediate-Risk Rectal Adenocarcinoma Selected by High-Resolution Magnetic Resonance Imaging: The GEMCAD 0801 Phase II Multicenter Trial. <i>Oncologist</i> , 2014, 19, 1042-1043.	1.9	66
69	First-line bevacizumab and capecitabine+oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study. <i>British Journal of Cancer</i> , 2014, 111, 241-248.	2.9	29
70	Early onset hypothyroidism as a predictor for progression-free survival (PFS) and overall survival (OS) benefit in patients with advanced renal cell carcinoma treated with first-line sunitinib.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15564-e15564.	0.8	0
71	Should be NICE have a Spanish NICE?. <i>Clinical and Translational Oncology</i> , 2013, 15, 501-502.	1.2	1
72	Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 45-81.	2.0	90

#	ARTICLE	IF	CITATIONS
73	Are we changing the way we treat older colorectal cancer patients? An update on therapeutic management strategies. <i>Colorectal Cancer</i> , 2013, 2, 279-283.	0.8	0
74	Correlation of hypertension and proteinuria with outcomes in elderly bevacizumab (BEV)-treated patients with metastatic colorectal cancer (mCRC): Analysis of the BECOX and BECA studies.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3589-3589.	0.8	0
75	Analysis of the Concordance in the EGFR Pathway Status Between Primary Tumors and Related Metastases of Colorectal Cancer Patients:Implications for Cancer Therapy. <i>Current Cancer Drug Targets</i> , 2012, 12, 124-131.	0.8	38
76	Management of colorectal cancer patients after resection of liver metastases: can we offer a tailored treatment?. <i>Clinical and Translational Oncology</i> , 2012, 14, 641-658.	1.2	4
77	Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3586-3586.	0.8	17
78	Comparison of magnetic resonance imaging and histopathological response to neoadjuvant chemotherapy in locally advanced rectal cancer: The GEMCAD 0801 trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14097-e14097.	0.8	0
79	On-line breath analysis of volatile organic compounds as a method for colorectal cancer detection.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1570-1570.	0.8	0
80	Symptom Clusters in Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2011, 42, 24-31.	0.6	78
81	Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. <i>Clinical and Translational Oncology</i> , 2011, 13, 536-544.	1.2	5
82	Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain. <i>Clinical and Translational Oncology</i> , 2011, 13, 798-804.	1.2	4
83	A Combined Strategy of SAGE and Quantitative PCR Provides a 13-Gene Signature that Predicts Preoperative Chemoradiotherapy Response and Outcome in Rectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4145-4154.	3.2	28
84	Development and Validation of a Prognostic Nomogram for Terminally Ill Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1613-1620.	3.0	77
85	Descriptive analysis of clinical factors affecting terminally ill cancer patients. <i>Supportive Care in Cancer</i> , 2009, 17, 261-269.	1.0	17
86	Consensus on the treatment of pancreatic cancer in Spain. <i>Clinical and Translational Oncology</i> , 2009, 11, 290-301.	1.2	4
87	Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 403-409.	1.1	8
88	Survival prediction in terminally ill cancer patients: Description and validation of a new predictive score. <i>Journal of Clinical Oncology</i> , 2009, 27, 9595-9595.	0.8	0
89	UFT (tegafurâ€“uracil) in rectal cancer. <i>Annals of Oncology</i> , 2008, 19, 1371-1378.	0.6	16
90	XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. <i>British Journal of Cancer</i> , 2006, 94, 969-975.	2.9	114

#	ARTICLE	IF	CITATIONS
91	Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 419-426.	1.1	5
92	Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 527-531.	1.1	8
93	Phase II randomised trial of raltitrexed+oxaliplatin vs raltitrexed+irinotecan as first-line treatment in advanced colorectal cancer. <i>British Journal of Cancer</i> , 2005, 93, 1230-1235.	2.9	31
94	Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study. <i>British Journal of Cancer</i> , 2004, 90, 1502-1507.	2.9	19
95	Phase II study of neoadjuvant treatment of rectal cancer with oxaliplatin, raltitrexed and radiotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 3746-3746.	0.8	1
96	Phase II study of neoadjuvant treatment of rectal cancer with oxaliplatin, raltitrexed and radiotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 3746-3746.	0.8	3
97	Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 247-252.	1.1	37
98	Neoadjuvant therapy of rectal carcinoma with UFT+leucovorin plus radiotherapy. <i>Annals of Oncology</i> , 2002, 13, 730-736.	0.6	60
99	Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. <i>Annals of Oncology</i> , 2002, 13, 1756-1762.	0.6	31
100	Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. <i>Cancer</i> , 2000, 89, 1706-1713.	2.0	34
101	Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. , 1999, 86, 1463-1469.		60
102	Uracil and tegafur modulated with leucovorin. , 1997, 79, 1884-1889.		62
103	Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. <i>European Journal of Cancer</i> , 1995, 31, 2215-2219.	1.3	82
104	Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal. <i>Anticancer Research</i> , 1993, 13, 759-62.	0.5	16